News | April 25, 2024
Syngene International reports Q4 FY24 consolidated PAT at Rs. 188.6 Cr
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
Syngene International has reported total income of Rs. 933 crores during the period ended March 31, 2024
The company will closely work with the USFDA to address and respond to the observations in an expeditious manner
This approval helps address an urgent unmet need, with about half of people living with early-stage NSCLC experiencing disease recurrence following surgery, despite adjuvant chemotherapy
NexGard Spectra is a soft, flavourful monthly chew that kills fleas before they can lay eggs
The US Generics market has been witnessing significant pricing pressure leading to significant losses at Jubilant Cadista since FY2022 onwards.
Around 7% of the Indian population suffers from IBS
FDA has concluded that this inspection is 'closed'
Interim analysis of an ongoing 156-week extension study supports long-term safety, tolerability and efficacy of atogepant 60 mg to prevent chronic and episodic migraine
Ofloxacin Ophthalmic Solution USP 0.3% is indicated for treatment of eye infections caused during the conditions of conjunctivitis and corneal ulcers
SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva
Subscribe To Our Newsletter & Stay Updated
